Clinical CR was determined by maintaining a progression-free period for three years with monthly tumor marker (carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA15-3)) testing and imaging evaluations with US and CT every three months. This evidence concerns the gene CEACAM5 and neoplasm.